Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Food insecurity in pregnancy is associated with an increased risk for perinatal complications, according to a recent study.

Researchers examined the long-term effect of different responses to pediatric obesity treatment on critical health outcomes in young adulthood.

A recent study finds that genetically predicted rheumatoid arthritis is causally associated with prostate cancer.

Patients with axSpA and early-stage hypertension face elevated risks for CVEs, likely due to their high inflammatory burden.

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

A recent study finds that artificial intelligence techniques could be used to optimize in vitro fertilization treatment.